Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Universidade Federal Do Rio Grande Do Sul-ufrgs

Universidade De São Paulo-usp

Pharmos Corporation

Aviva Breuer

Raphael Mechoulam

Ruth Gallily

Ester Fride

Lumir Hanus

Aaron Garzon

Susanna Tchilibon

Flavio Pereira Kapczinski

Michal Horowitz

Jose Alexandre De Souza Crippa

Francisco Silveira Guimaraes

Jaime Eduardo Cecilio Hallak

Antonio Waldo Zuardi

Sumner H Burstein

William Devane

Itai A Bab

Esther Shohami

Anat Biegon

Linda Parker

Shimon Ben Shabat

Susana Tchilibon

Naama Mussai

David Panikashvili

Tzviel Sheskin

Esther Fride

Jose Alexandre Crippa

Jaime Eduardo Hallak

Linda Department Of Psychology Parker

Compositions that include certain phenyl substituted cyclohexenyl compounds are administered to a subject in a method for treating obesity or an associated disease or disorder or in a method of reducing food consumption or body weight.

Method for treating pain or associated condition or symptom

The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.

Fluorinated CBD compounds, compositions and uses thereof

Cyclohexenyl compounds, compositions comprising them and uses thereof

Provided are compositions including (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonist properties, methods of treating diseases or disorders with the pharmaceutical compositions, and processes for their preparation are also provided.

Compositions comprising CB receptor agonists, uses thereof and methods for their preparation

The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.

Anti-nausea and anti-vomiting activity of cannabidiol compounds

The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives. It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.

Pharmaceutical compositions comprising cannabidiol derivatives

The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.

Agonists specific for the peripheral cannabinoid receptor

The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.

The present invention relates to 2-arachidonylglycerol (2-AG) to be used as inhibitor of a tumor necrosis factor (TNF-&agr;), in the reduction of edema caused by closed head injury, in the reduction of neurological deficits caused by closed head injury and stroke and in treating pathological conditions caused by TNF-&agr; and/or by radical oxygen intermediates (ROI), in pharmaceutical composition for the same use comprising as active ingredient 2-AG. It comprises also the use of 2-AG and pharmaceutical compositions comprising same in the preparation of a medicament for the treatment of said indications and methods of treatment by 2-AG and pharmaceutical compositions comprising same for diseases caused by said indications.

2-arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-&agr; and neuroprotector of brain in closed head injury

The present invention relates to a compound of the general formula (I) which is a non-hydrolysable analogue of endogenous cannabinoids, which are found to be more potent therapeutic agents as they are more stable, for example, to hydrolytic cleavage in the gastrointestinal tract. The cannabinoid analogues of the invention have a therapeutic value. Therefore, pharmaceutical compositions comprising as active ingredient a therapeutically effective amount of at least one compound of the invention may be prepared. Such compositions may be used as anti-inflammatory, anti-asthmatic, analgetic, hypotensive, antiemetic or anti-spasmodic compositions, and as compositions for treating and/or preventing glaucoma or migraine, or as compositions for relieving symptoms of multiple sclerosis and mood stimulating compositions.

Synthetic endogenous cannabinoids analogues and uses thereof

(3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives

The invention relates to compounds of the formula ##STR1## having the (3S,4S) configuration and being essentially free of the (3R,4R) enantiomer, in which A--B indicates an optional 1(2) or 6(1) double bond, X is carboxy, carbalkoxy, or carboxamido, linked to the ring directly or through an alkylene linkage, G is halogen, alkyl, or oxy, and Y is alkyl, oxy, or oxyalkylene. The invention further relates to the synthesis of such compounds, and to pharmaceutical compositions and therapeutic methods in which such compounds may be employed.

Certain tetrahydrocannabinol-7-oic acid derivatives

Growing community of inventors

Jerusalem, Israel

Aviva Breuer